Global PD-1 Antibody Drug Market Growth 2026-2032
The global PD-1 Antibody Drug market size is predicted to grow from US$ 45050 million in 2025 to US$ 95900 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.
A PD-1 antibody drug is a monoclonal antibody that targets the Programmed Death-1 receptor to block the PD-1/PD-L1 immune-checkpoint pathway exploited by tumor cells, thereby restoring and enhancing T-cell antitumor activity. These products are typically manufactured using mammalian expression systems such as CHO cells in large-scale bioreactors, followed by protein purification, viral inactivation/clearance, formulation, and aseptic fill-finish. The upstream supply chain includes key raw materials such as cell-culture media, recombinant expression vectors, single-use bioreactor bags, chromatography resins, filtration membranes, buffers, stabilizers, and excipients, as well as critical bioprocess equipment including bioreactors, chromatography and filtration systems, in-line monitoring sensors, and aseptic filling lines. The overall value chain involves stringent quality control and GMP compliance and forms a high-barrier manufacturing ecosystem supporting modern cancer immunotherapy.In 2024, global sales of PD-1 antibody drugs reached 22.88 million vials, with an average price of USD 1,860 per vial, and corporate gross profit margins ranging between 60% and 70%.
In recent years, PD-1 antibody therapies have been incorporated into standard treatment pathways across multiple tumor types, with both real-world evidence and clinical trials demonstrating durable responses and manageable immune-related adverse events. This has established PD-1 inhibitors as a central component of modern cancer immunotherapy. At the same time, the competitive landscape has expanded from a few originator companies to a diverse environment including biosimilars, localized biologics, and next-generation formulations such as subcutaneous, long-acting, and bispecific candidates, reshaping prescribing trends and patient access patterns.
Looking ahead, several development directions are expected to shape the market. Combination therapies and indication expansion will continue to push therapeutic boundaries, including integration with targeted therapies, antibody-drug conjugates, and cell-based treatments. Patient stratification guided by biomarkers will make treatment more precise. Innovations in delivery route and formulation—such as subcutaneous injections, long-acting constructs, and biosimilars—will improve accessibility and influence pricing structures. Meanwhile, the emergence of bispecific and multi-target immunotherapies is becoming a crucial competitive direction for the next generation of oncology treatments.
Multiple forces are driving market expansion, including accumulating efficacy evidence that broadens clinical use, updates to medical guidelines, and increased adoption by oncologists. Regulatory bodies in several regions are speeding up reviews when sufficient evidence is available, and reimbursement mechanisms are gradually extending to immunotherapies. Advances in bioprocessing, single-use technologies, and contract manufacturing are strengthening manufacturing reliability and supporting regionalized production. At the same time, substantial differences in access and reimbursement across regions compel companies to adjust commercialization and localization strategies.
Despite this momentum, the field faces notable challenges. Immune-related adverse events require sustained management and education. In some tumor types, limited clinical benefit restricts the applicability of high-cost combination regimens. Increasing competition from biosimilars, domestic manufacturers, and novel modalities is driving price pressure and eroding market share for established therapies. Regulatory complexity, intellectual-property disputes, reimbursement negotiations, and uncertainty in the supply chain—exacerbated by geopolitical dynamics—all introduce risks that may affect commercialization timelines and global expansion strategies for PD-1 antibody drugs.
LP Information, Inc. (LPI) ' newest research report, the “PD-1 Antibody Drug Industry Forecast” looks at past sales and reviews total world PD-1 Antibody Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected PD-1 Antibody Drug sales for 2026 through 2032. With PD-1 Antibody Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 Antibody Drug industry.
This Insight Report provides a comprehensive analysis of the global PD-1 Antibody Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 Antibody Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 Antibody Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 Antibody Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 Antibody Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 Antibody Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
A PD-1 antibody drug is a monoclonal antibody that targets the Programmed Death-1 receptor to block the PD-1/PD-L1 immune-checkpoint pathway exploited by tumor cells, thereby restoring and enhancing T-cell antitumor activity. These products are typically manufactured using mammalian expression systems such as CHO cells in large-scale bioreactors, followed by protein purification, viral inactivation/clearance, formulation, and aseptic fill-finish. The upstream supply chain includes key raw materials such as cell-culture media, recombinant expression vectors, single-use bioreactor bags, chromatography resins, filtration membranes, buffers, stabilizers, and excipients, as well as critical bioprocess equipment including bioreactors, chromatography and filtration systems, in-line monitoring sensors, and aseptic filling lines. The overall value chain involves stringent quality control and GMP compliance and forms a high-barrier manufacturing ecosystem supporting modern cancer immunotherapy.In 2024, global sales of PD-1 antibody drugs reached 22.88 million vials, with an average price of USD 1,860 per vial, and corporate gross profit margins ranging between 60% and 70%.
In recent years, PD-1 antibody therapies have been incorporated into standard treatment pathways across multiple tumor types, with both real-world evidence and clinical trials demonstrating durable responses and manageable immune-related adverse events. This has established PD-1 inhibitors as a central component of modern cancer immunotherapy. At the same time, the competitive landscape has expanded from a few originator companies to a diverse environment including biosimilars, localized biologics, and next-generation formulations such as subcutaneous, long-acting, and bispecific candidates, reshaping prescribing trends and patient access patterns.
Looking ahead, several development directions are expected to shape the market. Combination therapies and indication expansion will continue to push therapeutic boundaries, including integration with targeted therapies, antibody-drug conjugates, and cell-based treatments. Patient stratification guided by biomarkers will make treatment more precise. Innovations in delivery route and formulation—such as subcutaneous injections, long-acting constructs, and biosimilars—will improve accessibility and influence pricing structures. Meanwhile, the emergence of bispecific and multi-target immunotherapies is becoming a crucial competitive direction for the next generation of oncology treatments.
Multiple forces are driving market expansion, including accumulating efficacy evidence that broadens clinical use, updates to medical guidelines, and increased adoption by oncologists. Regulatory bodies in several regions are speeding up reviews when sufficient evidence is available, and reimbursement mechanisms are gradually extending to immunotherapies. Advances in bioprocessing, single-use technologies, and contract manufacturing are strengthening manufacturing reliability and supporting regionalized production. At the same time, substantial differences in access and reimbursement across regions compel companies to adjust commercialization and localization strategies.
Despite this momentum, the field faces notable challenges. Immune-related adverse events require sustained management and education. In some tumor types, limited clinical benefit restricts the applicability of high-cost combination regimens. Increasing competition from biosimilars, domestic manufacturers, and novel modalities is driving price pressure and eroding market share for established therapies. Regulatory complexity, intellectual-property disputes, reimbursement negotiations, and uncertainty in the supply chain—exacerbated by geopolitical dynamics—all introduce risks that may affect commercialization timelines and global expansion strategies for PD-1 antibody drugs.
LP Information, Inc. (LPI) ' newest research report, the “PD-1 Antibody Drug Industry Forecast” looks at past sales and reviews total world PD-1 Antibody Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected PD-1 Antibody Drug sales for 2026 through 2032. With PD-1 Antibody Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-1 Antibody Drug industry.
This Insight Report provides a comprehensive analysis of the global PD-1 Antibody Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PD-1 Antibody Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-1 Antibody Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-1 Antibody Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-1 Antibody Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-1 Antibody Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Pembrolizumab
- Nivolumab
- Cemiplimab
- Toripalimab
- Sintilimab
- Tislelizumab
- Camrelizumab
- Penpulimab
- Retifanlimab
- Zimberelimab
- 100 mg / Vial
- 200 mg / Vial
- 240 mg / Vial
- Others
- Intravenous Injection
- Subcutaneous Injection
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Regeneron Pharmaceuticals
- Shanghai Junshi Biosciences
- Innovent Biologics
- Hengrui Pharma
- BeiGene
- Akeso, Inc.
- Zai Lab
- GSK
- Eisai
- What is the 10-year outlook for the global PD-1 Antibody Drug market?
- What factors are driving PD-1 Antibody Drug market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do PD-1 Antibody Drug market opportunities vary by end market size?
- How does PD-1 Antibody Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 Antibody Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PD-1 Antibody Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PD-1 Antibody Drug by Country/Region, 2021, 2025 & 2032
2.2 PD-1 Antibody Drug Segment by Type
2.2.1 Pembrolizumab
2.2.2 Nivolumab
2.2.3 Sindilimab
2.2.4 Toripalimab
2.2.5 Other
2.2.6 PD-1 Antibody Drug Sales by Type
2.2.6.1 Global PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
2.2.6.2 Global PD-1 Antibody Drug Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global PD-1 Antibody Drug Sale Price by Type (2021-2026)
2.3 PD-1 Antibody Drug Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Other
2.3.4 PD-1 Antibody Drug Sales by Application
2.3.4.1 Global PD-1 Antibody Drug Sale Market Share by Application (2021-2026)
2.3.4.2 Global PD-1 Antibody Drug Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global PD-1 Antibody Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PD-1 Antibody Drug Breakdown Data by Company
3.1.1 Global PD-1 Antibody Drug Annual Sales by Company (2021-2026)
3.1.2 Global PD-1 Antibody Drug Sales Market Share by Company (2021-2026)
3.2 Global PD-1 Antibody Drug Annual Revenue by Company (2021-2026)
3.2.1 Global PD-1 Antibody Drug Revenue by Company (2021-2026)
3.2.2 Global PD-1 Antibody Drug Revenue Market Share by Company (2021-2026)
3.3 Global PD-1 Antibody Drug Sale Price by Company
3.4 Key Manufacturers PD-1 Antibody Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 Antibody Drug Product Location Distribution
3.4.2 Players PD-1 Antibody Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PD-1 ANTIBODY DRUG BY GEOGRAPHIC REGION
4.1 World Historic PD-1 Antibody Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global PD-1 Antibody Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PD-1 Antibody Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PD-1 Antibody Drug Market Size by Country/Region (2021-2026)
4.2.1 Global PD-1 Antibody Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global PD-1 Antibody Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas PD-1 Antibody Drug Sales Growth
4.4 APAC PD-1 Antibody Drug Sales Growth
4.5 Europe PD-1 Antibody Drug Sales Growth
4.6 Middle East & Africa PD-1 Antibody Drug Sales Growth
5 AMERICAS
5.1 Americas PD-1 Antibody Drug Sales by Country
5.1.1 Americas PD-1 Antibody Drug Sales by Country (2021-2026)
5.1.2 Americas PD-1 Antibody Drug Revenue by Country (2021-2026)
5.2 Americas PD-1 Antibody Drug Sales by Type (2021-2026)
5.3 Americas PD-1 Antibody Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 Antibody Drug Sales by Region
6.1.1 APAC PD-1 Antibody Drug Sales by Region (2021-2026)
6.1.2 APAC PD-1 Antibody Drug Revenue by Region (2021-2026)
6.2 APAC PD-1 Antibody Drug Sales by Type (2021-2026)
6.3 APAC PD-1 Antibody Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1 Antibody Drug by Country
7.1.1 Europe PD-1 Antibody Drug Sales by Country (2021-2026)
7.1.2 Europe PD-1 Antibody Drug Revenue by Country (2021-2026)
7.2 Europe PD-1 Antibody Drug Sales by Type (2021-2026)
7.3 Europe PD-1 Antibody Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 Antibody Drug by Country
8.1.1 Middle East & Africa PD-1 Antibody Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa PD-1 Antibody Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa PD-1 Antibody Drug Sales by Type (2021-2026)
8.3 Middle East & Africa PD-1 Antibody Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 Antibody Drug
10.3 Manufacturing Process Analysis of PD-1 Antibody Drug
10.4 Industry Chain Structure of PD-1 Antibody Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 Antibody Drug Distributors
11.3 PD-1 Antibody Drug Customer
12 WORLD FORECAST REVIEW FOR PD-1 ANTIBODY DRUG BY GEOGRAPHIC REGION
12.1 Global PD-1 Antibody Drug Market Size Forecast by Region
12.1.1 Global PD-1 Antibody Drug Forecast by Region (2027-2032)
12.1.2 Global PD-1 Antibody Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PD-1 Antibody Drug Forecast by Type (2027-2032)
12.7 Global PD-1 Antibody Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis PD-1 Antibody Drug Product Portfolios and Specifications
13.1.3 Novartis PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Thermo Fisher
13.2.1 Thermo Fisher Company Information
13.2.2 Thermo Fisher PD-1 Antibody Drug Product Portfolios and Specifications
13.2.3 Thermo Fisher PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Thermo Fisher Main Business Overview
13.2.5 Thermo Fisher Latest Developments
13.3 InvivoGen
13.3.1 InvivoGen Company Information
13.3.2 InvivoGen PD-1 Antibody Drug Product Portfolios and Specifications
13.3.3 InvivoGen PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 InvivoGen Main Business Overview
13.3.5 InvivoGen Latest Developments
13.4 BioVision Inc.
13.4.1 BioVision Inc. Company Information
13.4.2 BioVision Inc. PD-1 Antibody Drug Product Portfolios and Specifications
13.4.3 BioVision Inc. PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioVision Inc. Main Business Overview
13.4.5 BioVision Inc. Latest Developments
13.5 Abcam
13.5.1 Abcam Company Information
13.5.2 Abcam PD-1 Antibody Drug Product Portfolios and Specifications
13.5.3 Abcam PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Abcam Main Business Overview
13.5.5 Abcam Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck PD-1 Antibody Drug Product Portfolios and Specifications
13.7.3 Merck PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 Ono Pharmaceutical Co., Ltd
13.8.1 Ono Pharmaceutical Co., Ltd Company Information
13.8.2 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
13.8.3 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Ono Pharmaceutical Co., Ltd Main Business Overview
13.8.5 Ono Pharmaceutical Co., Ltd Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly PD-1 Antibody Drug Product Portfolios and Specifications
13.9.3 Eli Lilly PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Chugai Pharmaceutical Co., Ltd
13.10.1 Chugai Pharmaceutical Co., Ltd Company Information
13.10.2 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
13.10.3 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Chugai Pharmaceutical Co., Ltd Main Business Overview
13.10.5 Chugai Pharmaceutical Co., Ltd Latest Developments
13.11 BeiGene
13.11.1 BeiGene Company Information
13.11.2 BeiGene PD-1 Antibody Drug Product Portfolios and Specifications
13.11.3 BeiGene PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 BeiGene Main Business Overview
13.11.5 BeiGene Latest Developments
13.12 AbbVie
13.12.1 AbbVie Company Information
13.12.2 AbbVie PD-1 Antibody Drug Product Portfolios and Specifications
13.12.3 AbbVie PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 AbbVie Main Business Overview
13.12.5 AbbVie Latest Developments
13.13 TG Therapeutics, Inc
13.13.1 TG Therapeutics, Inc Company Information
13.13.2 TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolios and Specifications
13.13.3 TG Therapeutics, Inc PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 TG Therapeutics, Inc Main Business Overview
13.13.5 TG Therapeutics, Inc Latest Developments
13.14 Beijing Yiqiao Shenzhou Technology Co., Ltd.
13.14.1 Beijing Yiqiao Shenzhou Technology Co., Ltd. Company Information
13.14.2 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolios and Specifications
13.14.3 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beijing Yiqiao Shenzhou Technology Co., Ltd. Main Business Overview
13.14.5 Beijing Yiqiao Shenzhou Technology Co., Ltd. Latest Developments
13.15 3SBio
13.15.1 3SBio Company Information
13.15.2 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
13.15.3 3SBio PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 3SBio Main Business Overview
13.15.5 3SBio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global PD-1 Antibody Drug Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for PD-1 Antibody Drug by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for PD-1 Antibody Drug by Country/Region, 2021, 2025 & 2032
2.2 PD-1 Antibody Drug Segment by Type
2.2.1 Pembrolizumab
2.2.2 Nivolumab
2.2.3 Sindilimab
2.2.4 Toripalimab
2.2.5 Other
2.2.6 PD-1 Antibody Drug Sales by Type
2.2.6.1 Global PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
2.2.6.2 Global PD-1 Antibody Drug Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global PD-1 Antibody Drug Sale Price by Type (2021-2026)
2.3 PD-1 Antibody Drug Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Other
2.3.4 PD-1 Antibody Drug Sales by Application
2.3.4.1 Global PD-1 Antibody Drug Sale Market Share by Application (2021-2026)
2.3.4.2 Global PD-1 Antibody Drug Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global PD-1 Antibody Drug Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global PD-1 Antibody Drug Breakdown Data by Company
3.1.1 Global PD-1 Antibody Drug Annual Sales by Company (2021-2026)
3.1.2 Global PD-1 Antibody Drug Sales Market Share by Company (2021-2026)
3.2 Global PD-1 Antibody Drug Annual Revenue by Company (2021-2026)
3.2.1 Global PD-1 Antibody Drug Revenue by Company (2021-2026)
3.2.2 Global PD-1 Antibody Drug Revenue Market Share by Company (2021-2026)
3.3 Global PD-1 Antibody Drug Sale Price by Company
3.4 Key Manufacturers PD-1 Antibody Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PD-1 Antibody Drug Product Location Distribution
3.4.2 Players PD-1 Antibody Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PD-1 ANTIBODY DRUG BY GEOGRAPHIC REGION
4.1 World Historic PD-1 Antibody Drug Market Size by Geographic Region (2021-2026)
4.1.1 Global PD-1 Antibody Drug Annual Sales by Geographic Region (2021-2026)
4.1.2 Global PD-1 Antibody Drug Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic PD-1 Antibody Drug Market Size by Country/Region (2021-2026)
4.2.1 Global PD-1 Antibody Drug Annual Sales by Country/Region (2021-2026)
4.2.2 Global PD-1 Antibody Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas PD-1 Antibody Drug Sales Growth
4.4 APAC PD-1 Antibody Drug Sales Growth
4.5 Europe PD-1 Antibody Drug Sales Growth
4.6 Middle East & Africa PD-1 Antibody Drug Sales Growth
5 AMERICAS
5.1 Americas PD-1 Antibody Drug Sales by Country
5.1.1 Americas PD-1 Antibody Drug Sales by Country (2021-2026)
5.1.2 Americas PD-1 Antibody Drug Revenue by Country (2021-2026)
5.2 Americas PD-1 Antibody Drug Sales by Type (2021-2026)
5.3 Americas PD-1 Antibody Drug Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-1 Antibody Drug Sales by Region
6.1.1 APAC PD-1 Antibody Drug Sales by Region (2021-2026)
6.1.2 APAC PD-1 Antibody Drug Revenue by Region (2021-2026)
6.2 APAC PD-1 Antibody Drug Sales by Type (2021-2026)
6.3 APAC PD-1 Antibody Drug Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe PD-1 Antibody Drug by Country
7.1.1 Europe PD-1 Antibody Drug Sales by Country (2021-2026)
7.1.2 Europe PD-1 Antibody Drug Revenue by Country (2021-2026)
7.2 Europe PD-1 Antibody Drug Sales by Type (2021-2026)
7.3 Europe PD-1 Antibody Drug Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa PD-1 Antibody Drug by Country
8.1.1 Middle East & Africa PD-1 Antibody Drug Sales by Country (2021-2026)
8.1.2 Middle East & Africa PD-1 Antibody Drug Revenue by Country (2021-2026)
8.2 Middle East & Africa PD-1 Antibody Drug Sales by Type (2021-2026)
8.3 Middle East & Africa PD-1 Antibody Drug Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PD-1 Antibody Drug
10.3 Manufacturing Process Analysis of PD-1 Antibody Drug
10.4 Industry Chain Structure of PD-1 Antibody Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PD-1 Antibody Drug Distributors
11.3 PD-1 Antibody Drug Customer
12 WORLD FORECAST REVIEW FOR PD-1 ANTIBODY DRUG BY GEOGRAPHIC REGION
12.1 Global PD-1 Antibody Drug Market Size Forecast by Region
12.1.1 Global PD-1 Antibody Drug Forecast by Region (2027-2032)
12.1.2 Global PD-1 Antibody Drug Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global PD-1 Antibody Drug Forecast by Type (2027-2032)
12.7 Global PD-1 Antibody Drug Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis PD-1 Antibody Drug Product Portfolios and Specifications
13.1.3 Novartis PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Thermo Fisher
13.2.1 Thermo Fisher Company Information
13.2.2 Thermo Fisher PD-1 Antibody Drug Product Portfolios and Specifications
13.2.3 Thermo Fisher PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Thermo Fisher Main Business Overview
13.2.5 Thermo Fisher Latest Developments
13.3 InvivoGen
13.3.1 InvivoGen Company Information
13.3.2 InvivoGen PD-1 Antibody Drug Product Portfolios and Specifications
13.3.3 InvivoGen PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 InvivoGen Main Business Overview
13.3.5 InvivoGen Latest Developments
13.4 BioVision Inc.
13.4.1 BioVision Inc. Company Information
13.4.2 BioVision Inc. PD-1 Antibody Drug Product Portfolios and Specifications
13.4.3 BioVision Inc. PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioVision Inc. Main Business Overview
13.4.5 BioVision Inc. Latest Developments
13.5 Abcam
13.5.1 Abcam Company Information
13.5.2 Abcam PD-1 Antibody Drug Product Portfolios and Specifications
13.5.3 Abcam PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Abcam Main Business Overview
13.5.5 Abcam Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolios and Specifications
13.6.3 Bristol-Myers Squibb PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Merck
13.7.1 Merck Company Information
13.7.2 Merck PD-1 Antibody Drug Product Portfolios and Specifications
13.7.3 Merck PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Merck Main Business Overview
13.7.5 Merck Latest Developments
13.8 Ono Pharmaceutical Co., Ltd
13.8.1 Ono Pharmaceutical Co., Ltd Company Information
13.8.2 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
13.8.3 Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Ono Pharmaceutical Co., Ltd Main Business Overview
13.8.5 Ono Pharmaceutical Co., Ltd Latest Developments
13.9 Eli Lilly
13.9.1 Eli Lilly Company Information
13.9.2 Eli Lilly PD-1 Antibody Drug Product Portfolios and Specifications
13.9.3 Eli Lilly PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Eli Lilly Main Business Overview
13.9.5 Eli Lilly Latest Developments
13.10 Chugai Pharmaceutical Co., Ltd
13.10.1 Chugai Pharmaceutical Co., Ltd Company Information
13.10.2 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
13.10.3 Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Chugai Pharmaceutical Co., Ltd Main Business Overview
13.10.5 Chugai Pharmaceutical Co., Ltd Latest Developments
13.11 BeiGene
13.11.1 BeiGene Company Information
13.11.2 BeiGene PD-1 Antibody Drug Product Portfolios and Specifications
13.11.3 BeiGene PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 BeiGene Main Business Overview
13.11.5 BeiGene Latest Developments
13.12 AbbVie
13.12.1 AbbVie Company Information
13.12.2 AbbVie PD-1 Antibody Drug Product Portfolios and Specifications
13.12.3 AbbVie PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 AbbVie Main Business Overview
13.12.5 AbbVie Latest Developments
13.13 TG Therapeutics, Inc
13.13.1 TG Therapeutics, Inc Company Information
13.13.2 TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolios and Specifications
13.13.3 TG Therapeutics, Inc PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 TG Therapeutics, Inc Main Business Overview
13.13.5 TG Therapeutics, Inc Latest Developments
13.14 Beijing Yiqiao Shenzhou Technology Co., Ltd.
13.14.1 Beijing Yiqiao Shenzhou Technology Co., Ltd. Company Information
13.14.2 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolios and Specifications
13.14.3 Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beijing Yiqiao Shenzhou Technology Co., Ltd. Main Business Overview
13.14.5 Beijing Yiqiao Shenzhou Technology Co., Ltd. Latest Developments
13.15 3SBio
13.15.1 3SBio Company Information
13.15.2 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
13.15.3 3SBio PD-1 Antibody Drug Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 3SBio Main Business Overview
13.15.5 3SBio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. PD-1 Antibody Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PD-1 Antibody Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pembrolizumab
Table 4. Major Players of Nivolumab
Table 5. Major Players of Sindilimab
Table 6. Major Players of Toripalimab
Table 7. Major Players of Other
Table 8. Global PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 9. Global PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Table 10. Global PD-1 Antibody Drug Revenue by Type (2021-2026) & ($ million)
Table 11. Global PD-1 Antibody Drug Revenue Market Share by Type (2021-2026)
Table 12. Global PD-1 Antibody Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global PD-1 Antibody Drug Sale by Application (2021-2026) & (K Units)
Table 14. Global PD-1 Antibody Drug Sale Market Share by Application (2021-2026)
Table 15. Global PD-1 Antibody Drug Revenue by Application (2021-2026) & ($ million)
Table 16. Global PD-1 Antibody Drug Revenue Market Share by Application (2021-2026)
Table 17. Global PD-1 Antibody Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global PD-1 Antibody Drug Sales by Company (2021-2026) & (K Units)
Table 19. Global PD-1 Antibody Drug Sales Market Share by Company (2021-2026)
Table 20. Global PD-1 Antibody Drug Revenue by Company (2021-2026) & ($ millions)
Table 21. Global PD-1 Antibody Drug Revenue Market Share by Company (2021-2026)
Table 22. Global PD-1 Antibody Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers PD-1 Antibody Drug Producing Area Distribution and Sales Area
Table 24. Players PD-1 Antibody Drug Products Offered
Table 25. PD-1 Antibody Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global PD-1 Antibody Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global PD-1 Antibody Drug Sales Market Share Geographic Region (2021-2026)
Table 30. Global PD-1 Antibody Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global PD-1 Antibody Drug Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global PD-1 Antibody Drug Sales Market Share by Country/Region (2021-2026)
Table 34. Global PD-1 Antibody Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global PD-1 Antibody Drug Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas PD-1 Antibody Drug Sales by Country (2021-2026) & (K Units)
Table 37. Americas PD-1 Antibody Drug Sales Market Share by Country (2021-2026)
Table 38. Americas PD-1 Antibody Drug Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 40. Americas PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 41. APAC PD-1 Antibody Drug Sales by Region (2021-2026) & (K Units)
Table 42. APAC PD-1 Antibody Drug Sales Market Share by Region (2021-2026)
Table 43. APAC PD-1 Antibody Drug Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 45. APAC PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 46. Europe PD-1 Antibody Drug Sales by Country (2021-2026) & (K Units)
Table 47. Europe PD-1 Antibody Drug Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 49. Europe PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa PD-1 Antibody Drug Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa PD-1 Antibody Drug Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of PD-1 Antibody Drug
Table 55. Key Market Challenges & Risks of PD-1 Antibody Drug
Table 56. Key Industry Trends of PD-1 Antibody Drug
Table 57. PD-1 Antibody Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. PD-1 Antibody Drug Distributors List
Table 60. PD-1 Antibody Drug Customer List
Table 61. Global PD-1 Antibody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global PD-1 Antibody Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas PD-1 Antibody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas PD-1 Antibody Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC PD-1 Antibody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC PD-1 Antibody Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe PD-1 Antibody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe PD-1 Antibody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa PD-1 Antibody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa PD-1 Antibody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global PD-1 Antibody Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global PD-1 Antibody Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global PD-1 Antibody Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global PD-1 Antibody Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. Novartis Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Novartis PD-1 Antibody Drug Product Portfolios and Specifications
Table 77. Novartis PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. Novartis Main Business
Table 79. Novartis Latest Developments
Table 80. Thermo Fisher Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Thermo Fisher PD-1 Antibody Drug Product Portfolios and Specifications
Table 82. Thermo Fisher PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Thermo Fisher Main Business
Table 84. Thermo Fisher Latest Developments
Table 85. InvivoGen Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. InvivoGen PD-1 Antibody Drug Product Portfolios and Specifications
Table 87. InvivoGen PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. InvivoGen Main Business
Table 89. InvivoGen Latest Developments
Table 90. BioVision Inc. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. BioVision Inc. PD-1 Antibody Drug Product Portfolios and Specifications
Table 92. BioVision Inc. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. BioVision Inc. Main Business
Table 94. BioVision Inc. Latest Developments
Table 95. Abcam Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Abcam PD-1 Antibody Drug Product Portfolios and Specifications
Table 97. Abcam PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Abcam Main Business
Table 99. Abcam Latest Developments
Table 100. Bristol-Myers Squibb Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolios and Specifications
Table 102. Bristol-Myers Squibb PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Bristol-Myers Squibb Main Business
Table 104. Bristol-Myers Squibb Latest Developments
Table 105. Merck Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Merck PD-1 Antibody Drug Product Portfolios and Specifications
Table 107. Merck PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Merck Main Business
Table 109. Merck Latest Developments
Table 110. Ono Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 112. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Ono Pharmaceutical Co., Ltd Main Business
Table 114. Ono Pharmaceutical Co., Ltd Latest Developments
Table 115. Eli Lilly Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Eli Lilly PD-1 Antibody Drug Product Portfolios and Specifications
Table 117. Eli Lilly PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Eli Lilly Main Business
Table 119. Eli Lilly Latest Developments
Table 120. Chugai Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 122. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Chugai Pharmaceutical Co., Ltd Main Business
Table 124. Chugai Pharmaceutical Co., Ltd Latest Developments
Table 125. BeiGene Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. BeiGene PD-1 Antibody Drug Product Portfolios and Specifications
Table 127. BeiGene PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. BeiGene Main Business
Table 129. BeiGene Latest Developments
Table 130. AbbVie Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. AbbVie PD-1 Antibody Drug Product Portfolios and Specifications
Table 132. AbbVie PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. AbbVie Main Business
Table 134. AbbVie Latest Developments
Table 135. TG Therapeutics, Inc Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolios and Specifications
Table 137. TG Therapeutics, Inc PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. TG Therapeutics, Inc Main Business
Table 139. TG Therapeutics, Inc Latest Developments
Table 140. Beijing Yiqiao Shenzhou Technology Co., Ltd. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolios and Specifications
Table 142. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. Beijing Yiqiao Shenzhou Technology Co., Ltd. Main Business
Table 144. Beijing Yiqiao Shenzhou Technology Co., Ltd. Latest Developments
Table 145. 3SBio Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
Table 147. 3SBio PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. 3SBio Main Business
Table 149. 3SBio Latest Developments
Table 1. PD-1 Antibody Drug Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. PD-1 Antibody Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Pembrolizumab
Table 4. Major Players of Nivolumab
Table 5. Major Players of Sindilimab
Table 6. Major Players of Toripalimab
Table 7. Major Players of Other
Table 8. Global PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 9. Global PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Table 10. Global PD-1 Antibody Drug Revenue by Type (2021-2026) & ($ million)
Table 11. Global PD-1 Antibody Drug Revenue Market Share by Type (2021-2026)
Table 12. Global PD-1 Antibody Drug Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global PD-1 Antibody Drug Sale by Application (2021-2026) & (K Units)
Table 14. Global PD-1 Antibody Drug Sale Market Share by Application (2021-2026)
Table 15. Global PD-1 Antibody Drug Revenue by Application (2021-2026) & ($ million)
Table 16. Global PD-1 Antibody Drug Revenue Market Share by Application (2021-2026)
Table 17. Global PD-1 Antibody Drug Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global PD-1 Antibody Drug Sales by Company (2021-2026) & (K Units)
Table 19. Global PD-1 Antibody Drug Sales Market Share by Company (2021-2026)
Table 20. Global PD-1 Antibody Drug Revenue by Company (2021-2026) & ($ millions)
Table 21. Global PD-1 Antibody Drug Revenue Market Share by Company (2021-2026)
Table 22. Global PD-1 Antibody Drug Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers PD-1 Antibody Drug Producing Area Distribution and Sales Area
Table 24. Players PD-1 Antibody Drug Products Offered
Table 25. PD-1 Antibody Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global PD-1 Antibody Drug Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global PD-1 Antibody Drug Sales Market Share Geographic Region (2021-2026)
Table 30. Global PD-1 Antibody Drug Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global PD-1 Antibody Drug Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global PD-1 Antibody Drug Sales Market Share by Country/Region (2021-2026)
Table 34. Global PD-1 Antibody Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global PD-1 Antibody Drug Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas PD-1 Antibody Drug Sales by Country (2021-2026) & (K Units)
Table 37. Americas PD-1 Antibody Drug Sales Market Share by Country (2021-2026)
Table 38. Americas PD-1 Antibody Drug Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 40. Americas PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 41. APAC PD-1 Antibody Drug Sales by Region (2021-2026) & (K Units)
Table 42. APAC PD-1 Antibody Drug Sales Market Share by Region (2021-2026)
Table 43. APAC PD-1 Antibody Drug Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 45. APAC PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 46. Europe PD-1 Antibody Drug Sales by Country (2021-2026) & (K Units)
Table 47. Europe PD-1 Antibody Drug Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 49. Europe PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa PD-1 Antibody Drug Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa PD-1 Antibody Drug Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa PD-1 Antibody Drug Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa PD-1 Antibody Drug Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of PD-1 Antibody Drug
Table 55. Key Market Challenges & Risks of PD-1 Antibody Drug
Table 56. Key Industry Trends of PD-1 Antibody Drug
Table 57. PD-1 Antibody Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. PD-1 Antibody Drug Distributors List
Table 60. PD-1 Antibody Drug Customer List
Table 61. Global PD-1 Antibody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global PD-1 Antibody Drug Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas PD-1 Antibody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas PD-1 Antibody Drug Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC PD-1 Antibody Drug Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC PD-1 Antibody Drug Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe PD-1 Antibody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe PD-1 Antibody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa PD-1 Antibody Drug Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa PD-1 Antibody Drug Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global PD-1 Antibody Drug Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global PD-1 Antibody Drug Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global PD-1 Antibody Drug Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global PD-1 Antibody Drug Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. Novartis Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. Novartis PD-1 Antibody Drug Product Portfolios and Specifications
Table 77. Novartis PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. Novartis Main Business
Table 79. Novartis Latest Developments
Table 80. Thermo Fisher Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Thermo Fisher PD-1 Antibody Drug Product Portfolios and Specifications
Table 82. Thermo Fisher PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Thermo Fisher Main Business
Table 84. Thermo Fisher Latest Developments
Table 85. InvivoGen Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. InvivoGen PD-1 Antibody Drug Product Portfolios and Specifications
Table 87. InvivoGen PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. InvivoGen Main Business
Table 89. InvivoGen Latest Developments
Table 90. BioVision Inc. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. BioVision Inc. PD-1 Antibody Drug Product Portfolios and Specifications
Table 92. BioVision Inc. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. BioVision Inc. Main Business
Table 94. BioVision Inc. Latest Developments
Table 95. Abcam Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Abcam PD-1 Antibody Drug Product Portfolios and Specifications
Table 97. Abcam PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Abcam Main Business
Table 99. Abcam Latest Developments
Table 100. Bristol-Myers Squibb Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolios and Specifications
Table 102. Bristol-Myers Squibb PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Bristol-Myers Squibb Main Business
Table 104. Bristol-Myers Squibb Latest Developments
Table 105. Merck Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Merck PD-1 Antibody Drug Product Portfolios and Specifications
Table 107. Merck PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Merck Main Business
Table 109. Merck Latest Developments
Table 110. Ono Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 112. Ono Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Ono Pharmaceutical Co., Ltd Main Business
Table 114. Ono Pharmaceutical Co., Ltd Latest Developments
Table 115. Eli Lilly Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Eli Lilly PD-1 Antibody Drug Product Portfolios and Specifications
Table 117. Eli Lilly PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Eli Lilly Main Business
Table 119. Eli Lilly Latest Developments
Table 120. Chugai Pharmaceutical Co., Ltd Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Product Portfolios and Specifications
Table 122. Chugai Pharmaceutical Co., Ltd PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Chugai Pharmaceutical Co., Ltd Main Business
Table 124. Chugai Pharmaceutical Co., Ltd Latest Developments
Table 125. BeiGene Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. BeiGene PD-1 Antibody Drug Product Portfolios and Specifications
Table 127. BeiGene PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. BeiGene Main Business
Table 129. BeiGene Latest Developments
Table 130. AbbVie Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. AbbVie PD-1 Antibody Drug Product Portfolios and Specifications
Table 132. AbbVie PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. AbbVie Main Business
Table 134. AbbVie Latest Developments
Table 135. TG Therapeutics, Inc Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. TG Therapeutics, Inc PD-1 Antibody Drug Product Portfolios and Specifications
Table 137. TG Therapeutics, Inc PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. TG Therapeutics, Inc Main Business
Table 139. TG Therapeutics, Inc Latest Developments
Table 140. Beijing Yiqiao Shenzhou Technology Co., Ltd. Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Product Portfolios and Specifications
Table 142. Beijing Yiqiao Shenzhou Technology Co., Ltd. PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. Beijing Yiqiao Shenzhou Technology Co., Ltd. Main Business
Table 144. Beijing Yiqiao Shenzhou Technology Co., Ltd. Latest Developments
Table 145. 3SBio Basic Information, PD-1 Antibody Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. 3SBio PD-1 Antibody Drug Product Portfolios and Specifications
Table 147. 3SBio PD-1 Antibody Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. 3SBio Main Business
Table 149. 3SBio Latest Developments
LIST OF FIGURES
Figure 1. Picture of PD-1 Antibody Drug
Figure 2. PD-1 Antibody Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 Antibody Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global PD-1 Antibody Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PD-1 Antibody Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PD-1 Antibody Drug Sales Market Share by Country/Region (2025)
Figure 10. PD-1 Antibody Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pembrolizumab
Figure 12. Product Picture of Nivolumab
Figure 13. Product Picture of Sindilimab
Figure 14. Product Picture of Toripalimab
Figure 15. Product Picture of Other
Figure 16. Global PD-1 Antibody Drug Sales Market Share by Type in 2026
Figure 17. Global PD-1 Antibody Drug Revenue Market Share by Type (2021-2026)
Figure 18. PD-1 Antibody Drug Consumed in Hospital
Figure 19. Global PD-1 Antibody Drug Market: Hospital (2021-2026) & (K Units)
Figure 20. PD-1 Antibody Drug Consumed in Clinic
Figure 21. Global PD-1 Antibody Drug Market: Clinic (2021-2026) & (K Units)
Figure 22. PD-1 Antibody Drug Consumed in Other
Figure 23. Global PD-1 Antibody Drug Market: Other (2021-2026) & (K Units)
Figure 24. Global PD-1 Antibody Drug Sale Market Share by Application (2025)
Figure 25. Global PD-1 Antibody Drug Revenue Market Share by Application in 2026
Figure 26. PD-1 Antibody Drug Sales by Company in 2026 (K Units)
Figure 27. Global PD-1 Antibody Drug Sales Market Share by Company in 2026
Figure 28. PD-1 Antibody Drug Revenue by Company in 2026 ($ millions)
Figure 29. Global PD-1 Antibody Drug Revenue Market Share by Company in 2026
Figure 30. Global PD-1 Antibody Drug Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region in 2026
Figure 32. Americas PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 33. Americas PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 34. APAC PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 35. APAC PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 36. Europe PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 37. Europe PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 40. Americas PD-1 Antibody Drug Sales Market Share by Country in 2026
Figure 41. Americas PD-1 Antibody Drug Revenue Market Share by Country (2021-2026)
Figure 42. Americas PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 43. Americas PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 44. United States PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC PD-1 Antibody Drug Sales Market Share by Region in 2026
Figure 49. APAC PD-1 Antibody Drug Revenue Market Share by Region (2021-2026)
Figure 50. APAC PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 51. APAC PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 52. China PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 56. India PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe PD-1 Antibody Drug Sales Market Share by Country in 2026
Figure 60. Europe PD-1 Antibody Drug Revenue Market Share by Country (2021-2026)
Figure 61. Europe PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 62. Europe PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 63. Germany PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 64. France PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. UK PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 71. Egypt PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of PD-1 Antibody Drug in 2026
Figure 77. Manufacturing Process Analysis of PD-1 Antibody Drug
Figure 78. Industry Chain Structure of PD-1 Antibody Drug
Figure 79. Channels of Distribution
Figure 80. Global PD-1 Antibody Drug Sales Market Forecast by Region (2027-2032)
Figure 81. Global PD-1 Antibody Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global PD-1 Antibody Drug Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global PD-1 Antibody Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global PD-1 Antibody Drug Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global PD-1 Antibody Drug Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of PD-1 Antibody Drug
Figure 2. PD-1 Antibody Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global PD-1 Antibody Drug Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global PD-1 Antibody Drug Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. PD-1 Antibody Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. PD-1 Antibody Drug Sales Market Share by Country/Region (2025)
Figure 10. PD-1 Antibody Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Pembrolizumab
Figure 12. Product Picture of Nivolumab
Figure 13. Product Picture of Sindilimab
Figure 14. Product Picture of Toripalimab
Figure 15. Product Picture of Other
Figure 16. Global PD-1 Antibody Drug Sales Market Share by Type in 2026
Figure 17. Global PD-1 Antibody Drug Revenue Market Share by Type (2021-2026)
Figure 18. PD-1 Antibody Drug Consumed in Hospital
Figure 19. Global PD-1 Antibody Drug Market: Hospital (2021-2026) & (K Units)
Figure 20. PD-1 Antibody Drug Consumed in Clinic
Figure 21. Global PD-1 Antibody Drug Market: Clinic (2021-2026) & (K Units)
Figure 22. PD-1 Antibody Drug Consumed in Other
Figure 23. Global PD-1 Antibody Drug Market: Other (2021-2026) & (K Units)
Figure 24. Global PD-1 Antibody Drug Sale Market Share by Application (2025)
Figure 25. Global PD-1 Antibody Drug Revenue Market Share by Application in 2026
Figure 26. PD-1 Antibody Drug Sales by Company in 2026 (K Units)
Figure 27. Global PD-1 Antibody Drug Sales Market Share by Company in 2026
Figure 28. PD-1 Antibody Drug Revenue by Company in 2026 ($ millions)
Figure 29. Global PD-1 Antibody Drug Revenue Market Share by Company in 2026
Figure 30. Global PD-1 Antibody Drug Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global PD-1 Antibody Drug Revenue Market Share by Geographic Region in 2026
Figure 32. Americas PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 33. Americas PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 34. APAC PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 35. APAC PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 36. Europe PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 37. Europe PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa PD-1 Antibody Drug Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa PD-1 Antibody Drug Revenue 2021-2026 ($ millions)
Figure 40. Americas PD-1 Antibody Drug Sales Market Share by Country in 2026
Figure 41. Americas PD-1 Antibody Drug Revenue Market Share by Country (2021-2026)
Figure 42. Americas PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 43. Americas PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 44. United States PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC PD-1 Antibody Drug Sales Market Share by Region in 2026
Figure 49. APAC PD-1 Antibody Drug Revenue Market Share by Region (2021-2026)
Figure 50. APAC PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 51. APAC PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 52. China PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 56. India PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe PD-1 Antibody Drug Sales Market Share by Country in 2026
Figure 60. Europe PD-1 Antibody Drug Revenue Market Share by Country (2021-2026)
Figure 61. Europe PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 62. Europe PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 63. Germany PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 64. France PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 65. UK PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa PD-1 Antibody Drug Sales Market Share by Application (2021-2026)
Figure 71. Egypt PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries PD-1 Antibody Drug Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of PD-1 Antibody Drug in 2026
Figure 77. Manufacturing Process Analysis of PD-1 Antibody Drug
Figure 78. Industry Chain Structure of PD-1 Antibody Drug
Figure 79. Channels of Distribution
Figure 80. Global PD-1 Antibody Drug Sales Market Forecast by Region (2027-2032)
Figure 81. Global PD-1 Antibody Drug Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global PD-1 Antibody Drug Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global PD-1 Antibody Drug Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global PD-1 Antibody Drug Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global PD-1 Antibody Drug Revenue Market Share Forecast by Application (2027-2032)
